Malta vs Serbia: Death rate from Parkinson's disease
Malta
11.61 deaths per 100,000 people
in 2021
Serbia
11.16 deaths per 100,000 people
in 2021
Malta rank
16th
Serbia rank
19th
Death rate from Parkinson's disease over time
- Malta
- Serbia
How they compare
Malta currently reports 11.61 deaths per 100,000 people against 11.16 deaths per 100,000 people in Serbia, a difference of 0.45 deaths per 100,000 people.
Across all 22 years both countries report, Malta has been ahead every year.
Malta ranks 16th and Serbia ranks 19th of 194 countries.
Malta has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Malta | Serbia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 8.68 deaths per 100,000 people | 4.94 deaths per 100,000 people | 3.74 deaths per 100,000 people | Malta |
| 2010s | 10.01 deaths per 100,000 people | 7.84 deaths per 100,000 people | 2.17 deaths per 100,000 people | Malta |
| 2020s | 11.27 deaths per 100,000 people | 10.8 deaths per 100,000 people | 0.475 deaths per 100,000 people | Malta |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher death rate from parkinson's disease, Malta or Serbia?
- Malta, at 11.61 deaths per 100,000 people against 11.16 deaths per 100,000 people in Serbia as of 2021.
- What is the difference in death rate from parkinson's disease between Malta and Serbia?
- 0.45 deaths per 100,000 people, with Malta ahead.
- How many years of comparable data are there for Malta and Serbia?
- 22 years are reported by both, from 2000 to 2021.
- How do Malta and Serbia rank globally for death rate from parkinson's disease?
- Malta ranks 16th and Serbia ranks 19th of 194 countries.
- Where does this data come from?
- World Health Organization (2024) β with major processing by Our World in Data, published as Death rate from Parkinson's disease. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of deaths from parkinson disease in both sexes, per 100,000 people.